Evidence for a Cystic Fibrosis Enteropathy.

Previous studies have suggested the existence of enteropathy in cystic fibrosis (CF), which may contribute to intestinal function impairment, a poor nutritional status and decline in lung function. This study evaluated enterocyte damage and intestinal inflammation in CF and studied its associations...

Full description

Bibliographic Details
Main Authors: Marlou P M Adriaanse, Linda J T M van der Sande, Anita M van den Neucker, Paul P C A Menheere, Edward Dompeling, Wim A Buurman, Anita C E Vreugdenhil
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4617711?pdf=render
id doaj-640f99e36b3a44198082de8c7e887f9f
record_format Article
spelling doaj-640f99e36b3a44198082de8c7e887f9f2020-11-24T21:39:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011010e013806210.1371/journal.pone.0138062Evidence for a Cystic Fibrosis Enteropathy.Marlou P M AdriaanseLinda J T M van der SandeAnita M van den NeuckerPaul P C A MenheereEdward DompelingWim A BuurmanAnita C E VreugdenhilPrevious studies have suggested the existence of enteropathy in cystic fibrosis (CF), which may contribute to intestinal function impairment, a poor nutritional status and decline in lung function. This study evaluated enterocyte damage and intestinal inflammation in CF and studied its associations with nutritional status, CF-related morbidities such as impaired lung function and diabetes, and medication use.Sixty-eight CF patients and 107 controls were studied. Levels of serum intestinal-fatty acid binding protein (I-FABP), a specific marker for enterocyte damage, were retrospectively determined. The faecal intestinal inflammation marker calprotectin was prospectively studied. Nutritional status, lung function (FEV1), exocrine pancreatic insufficiency (EPI), CF-related diabetes (CFRD) and use of proton pump inhibitors (PPI) were obtained from the medical charts.Serum I-FABP levels were elevated in CF patients as compared with controls (p<0.001), and correlated negatively with FEV1 predicted value in children (r-.734, p<0.05). Faecal calprotectin level was elevated in 93% of CF patients, and correlated negatively with FEV1 predicted value in adults (r-.484, p<0.05). No correlation was found between calprotectin levels in faeces and sputum. Faecal calprotectin level was significantly associated with the presence of CFRD, EPI, and PPI use.This study demonstrated enterocyte damage and intestinal inflammation in CF patients, and provides evidence for an inverse correlation between enteropathy and lung function. The presented associations of enteropathy with important CF-related morbidities further emphasize the clinical relevance.http://europepmc.org/articles/PMC4617711?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Marlou P M Adriaanse
Linda J T M van der Sande
Anita M van den Neucker
Paul P C A Menheere
Edward Dompeling
Wim A Buurman
Anita C E Vreugdenhil
spellingShingle Marlou P M Adriaanse
Linda J T M van der Sande
Anita M van den Neucker
Paul P C A Menheere
Edward Dompeling
Wim A Buurman
Anita C E Vreugdenhil
Evidence for a Cystic Fibrosis Enteropathy.
PLoS ONE
author_facet Marlou P M Adriaanse
Linda J T M van der Sande
Anita M van den Neucker
Paul P C A Menheere
Edward Dompeling
Wim A Buurman
Anita C E Vreugdenhil
author_sort Marlou P M Adriaanse
title Evidence for a Cystic Fibrosis Enteropathy.
title_short Evidence for a Cystic Fibrosis Enteropathy.
title_full Evidence for a Cystic Fibrosis Enteropathy.
title_fullStr Evidence for a Cystic Fibrosis Enteropathy.
title_full_unstemmed Evidence for a Cystic Fibrosis Enteropathy.
title_sort evidence for a cystic fibrosis enteropathy.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description Previous studies have suggested the existence of enteropathy in cystic fibrosis (CF), which may contribute to intestinal function impairment, a poor nutritional status and decline in lung function. This study evaluated enterocyte damage and intestinal inflammation in CF and studied its associations with nutritional status, CF-related morbidities such as impaired lung function and diabetes, and medication use.Sixty-eight CF patients and 107 controls were studied. Levels of serum intestinal-fatty acid binding protein (I-FABP), a specific marker for enterocyte damage, were retrospectively determined. The faecal intestinal inflammation marker calprotectin was prospectively studied. Nutritional status, lung function (FEV1), exocrine pancreatic insufficiency (EPI), CF-related diabetes (CFRD) and use of proton pump inhibitors (PPI) were obtained from the medical charts.Serum I-FABP levels were elevated in CF patients as compared with controls (p<0.001), and correlated negatively with FEV1 predicted value in children (r-.734, p<0.05). Faecal calprotectin level was elevated in 93% of CF patients, and correlated negatively with FEV1 predicted value in adults (r-.484, p<0.05). No correlation was found between calprotectin levels in faeces and sputum. Faecal calprotectin level was significantly associated with the presence of CFRD, EPI, and PPI use.This study demonstrated enterocyte damage and intestinal inflammation in CF patients, and provides evidence for an inverse correlation between enteropathy and lung function. The presented associations of enteropathy with important CF-related morbidities further emphasize the clinical relevance.
url http://europepmc.org/articles/PMC4617711?pdf=render
work_keys_str_mv AT marloupmadriaanse evidenceforacysticfibrosisenteropathy
AT lindajtmvandersande evidenceforacysticfibrosisenteropathy
AT anitamvandenneucker evidenceforacysticfibrosisenteropathy
AT paulpcamenheere evidenceforacysticfibrosisenteropathy
AT edwarddompeling evidenceforacysticfibrosisenteropathy
AT wimabuurman evidenceforacysticfibrosisenteropathy
AT anitacevreugdenhil evidenceforacysticfibrosisenteropathy
_version_ 1725933291525111808